BiCAPPA

Cat. No.:	HY-138865
CAS No.:	119662-55-4
Molecular Formula:	$C_{38}H_{40}Cl_2N_6O_2$
Molecular Weight:	683.67
Target:	Others
Pathway:	Others
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 4.65 mg/mL (6.80 mM; ultrasonic and warming and adjust pH to 9 with 1M NaOH and heat to 60°C)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	1.4627 mL	7.3135 mL	14.6269 mL
	5 mM	0.2925 mL	1.4627 mL	2.9254 mL
	10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

BiCAPPA is the first bivalent antiprion ligand. BiCAPPA can decrease infectious conformational form of prion protein (PrP^{Sc}) from scrapie-infected cells, with an EC_{50} of 0.32 μM[1][2].

In Vitro

BiCAPPA (10 nM-2 μM; 5 d) decreases proteinase K-resistant PrP^{Sc} from scrapie-infected mouse hypothalamus cells, with an EC_{50} of 0.32 μM[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Uliassi E, et, al. 10-Medicinal Chemistry of Hybrids for Neurodegenerative Diseases. Design of Hybrid Molecules for Drug Development. 2017, Pages 259-277.

[2]. Bongarzone S, et, al. Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent anti-prion compound. J Med Chem. 2010 Nov 25;53(22):8197-201.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA